Form 8-K - Current report:
SEC Accession No. 0001437749-25-001113
Filing Date
2025-01-14
Accepted
2025-01-14 16:12:17
Documents
14
Period of Report
2025-01-07
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 FORM 8-K nrxp20250114_8k.htm   iXBRL 8-K 26198
  Complete submission text file 0001437749-25-001113.txt   178010

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA nrxp-20250107.xsd EX-101.SCH 3911
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nrxp-20250107_def.xml EX-101.DEF 13856
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE nrxp-20250107_lab.xml EX-101.LAB 18278
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nrxp-20250107_pre.xml EX-101.PRE 13888
16 EXTRACTED XBRL INSTANCE DOCUMENT nrxp20250114_8k_htm.xml XML 4969
Mailing Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801
Business Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801 484-254-6134
NRX Pharmaceuticals, Inc. (Filer) CIK: 0001719406 (see all company filings)

EIN.: 822844431 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38302 | Film No.: 25529506
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)